BioSpace News Archive

Nearly one year after it was launched by Pfizer and Bain Capital, Cerevel Therapeutics has tapped industry veteran Tony Coles as its chief executive officer.

Do you wake up every morning dreading going to work? If this happens to you even once a week, it may be time to start looking for a new gig.

There are things to negotiate in a job offer other than just money. You can begin your negotiation using this comprehensive guide that will tell you what to do and what not to.

Shares of ACADIA Pharmaceuticals are up nearly 70% after the company announced it halted a Phase III psychosis trial early after its Parkinson’s disease drug Nuplazid hit primary endpoints and positioned the company to seek another potential regulatory approval.

The rapid growth of Saudi Arabia’s pharmaceutical market will be placed under the spotlight at the forthcoming CPhI Middle East and Africa event, as the latest industry data reveals the Kingdom’s pharmaceutical market is expected to be valued at $10.74 billion (SR40.1 billion) by 2023.

Soricimed Biopharma Inc. announced that it has entered into a strategic alliance with Image Analysis Group, a UK-based company with unique expertise in medical imaging and artificial intelligence-based image analytics, whereby the companies will join their efforts in the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.

The U.S. Food and Drug Administration (FDA) gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Purdue Pharma may file for bankruptcy this week after negotiations over a multi-billion opioid claims settlement have stalled, multiple sources are reporting.

Amgen shares dropped 4.2% in pre-market trading at good but not amazing results in an early-stage trial of AMG 510 in in patients with previously treated KRAS G12C-mutated solid tumors.

There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.